Cancer Research Projects | Ohio State University | James Cancer Hospital | |
| Our Mission: |
[Close] |
| FORE Cancer Research was formed as a grass roots vehicle to help raise funds and awareness for cancer research. Our goal is to raise $1 million dollars through the help of the FORE Cancer Research Charity Pro-Am Golf Event, the Give 18 FORE Cancer Research campaign, and individual donations. Together we CAN make a difference and help put an end, once and for all, to this terrible disease. |
|
|
|
|
|
Total money raised FORE Cancer Research: $531,717* |
FORE Cancer Research is a 501.c.3 organization. |
| * Includes matching funds. |
|
|
|
 |
|
|
| The goal and only mission of FORE Cancer Research is to raise as much money as possible to support critical cancer research projects by some of the country’s leading doctors and scientists. By supporting cancer research you can ensure that innovation, greater understanding of the disease, discoveries and more effective cancer immunotherapies will continue. |
|
| We are proud to have supported the following projects: |
|
| | Pre clinical and Clinical studies of Combination HER-2 /neu (2009/2010) | | | Pravin T. P Kaumaya, PhD - The Ohio State University | |
The American Cancer Society estimates that 21,550 new cases of ovarian will be diagnosed in the US in 2009 with 14,600 deaths predicted. Of 192,370 newly diagnosed breast cancer patients, some 40,170 people will die from the disease. Ovarian Cancer is the second most common gynecologic cancer, with an incidence of about 15 cases per 100,000 women in western countries, and approximately 250,000 new cases and 125,00 deaths worldwide annually.
The NCI Strategic plan to defeat Cancer by 2015 is in tune with the Comprehensive Cancer Center goals: To improve people’s lives through innovation in research, education and patient care. Thus, the goals of developing “effective treatments to treat malignancy by either destroying all cancer cells or modulating and controlling metastases both with minimal harm to healthy tissue” mean integrating preclinical and clinical research and to translating research into high-quality patient care for residents of central Ohio and beyond. That means developing novel prophylactic as well as therapeutic vaccines and treatments. Stimulating the immune system to destroy tumor cells has long been a hope, and the realization of this dream is beginning to show signs of success.
Click here for full document
Dr. Kaumaya’s lab website
|
| | | | | | Discovery of a K-Ras Inhibitor for the Treatment of Lung Cancer in Women (2008) | | | Dr. Roger Briesewitz/Dr. Miguel Villalona/Dr. Dehua Pei - The Ohio State University | |
Lung cancer is the second most common malignancy in women after breast cancer1. Although breast cancer is more prevalent, lung cancer is the leading cause of cancer mortality in women, accounting for 26% of all cancer deaths1. Over the last 30 years, the incidence of lung cancer in women has increased fourfold1. This dramatic increase has been labeled a “contemporary epidemic” 2. Much of the dramatic increase in lung cancer observed in women appears to be based on the fact that women began to smoke cigarettes in increasing numbers starting in the 1940s and peaking in the 1970s. Despite the adverse risk effect of smoking, lung cancer may also develop in men and women who have never smoked. Compared to men, women in fact appear to be at a higher risk of developing lung cancer, suggesting sex-specific differences that promote the development of the disease3.
Our current therapeutic options for the treatment of lung cancer are very limited. 72% of all women diagnosed with lung cancer will eventually succumb to the disease despite treatment1. Novel therapeutic approaches are desperately needed to improve the odds of survival. In recent years we have gained important insights into the underlying genetic aberrations that cause lung cancer. Based on these insights we may be able to develop targeted therapeutics that are directed against the cancer cells and that, ideally, have only limited detrimental effects on healthy cells.
Click here for full document
|
| | | | | | The Role of microRNA in the Progression of Malignant Melanoma (2007) | | | Gregory B. Lesinski, Ph.D. - The Ohio State University | | |
"We are investigating whether small nucleic acid sequences, called microRNA can serve as markers to predict whether ‘borderline’ skin lesions will develop into melanoma, the most deadly form of skin cancer. Our preliminary research has shown that two specific microRNA sequences (microRNA-21 and microRNA-155) are more prevalent in biopsies from patients with melanoma when compared to patients with benign, non-cancerous biopsies. We will determine whether microRNA-21 and microRNA-155 make melanoma cells more aggressive and determine if the level of mircoRNA can predict whether borderline skin lesions become cancerous."
|
| | | |
|
|
|